(P-533) CD4 T-cell, CD4/CD8 Ratio Improvement and a General Reduction in Inflammatory Biomarkers with Low-Level Viremia (LLV) up to Week 192 with Fostemsavir (FTR)-Based Regimens in Individuals with Multidrug-Resistant (MDR) HIV-1

Thursday, October 17, 2024

12:15 PM – 1:30 PM US PT

Location: Halls JK

Co-Author(s)

Vincenzo Spagnuolo, MD

Assistant Professor
Vita-Salute San Raffaele University; Unit of Infectious Diseases, IRCCS, San Raffaele Scientific Institute
Milan, Emilia-Romagna, Italy
NG

Natalia Gregori, MD

ViiV Healthcare
Verona, Veneto, Italy
IM

Iacopo Marcon, PhD

ViiV Healthcare
Verona, Veneto, Italy
FD

Fangfang Du, MS in Statistics

Temple University
Chesterbrook, Pennsylvania, United States
BL

Bo Li, PhD

GSK
Collegeville, Pennsylvania, United States
MW

Marcia Wang, PhD

GlaxoSmithKline
Upper Providence, Pennsylvania, United States

Alftan Dyson, PharmD (she/her/hers)

Regional Medical Lead & US DEI Medical Engagement Lead
ViiV Healthcare
Durham, North Carolina, United States